Earnings Analyses

Reported results, market expectations and a look at the next quarter.

Verdicts Across Listed Reports7 Analyses

BUY4

HOLD3

SELL0

Wednesday, October 21Pre-Market

Thermo Fisher Scientific

TMO · Q3 2026Life Sciences · Lab Equipment and Biopharma Services

62/ 100

VerdictHOLD

Thermo Fisher beat expectations on revenue and earnings and raised its full-year guidance. The stock fell before the open, then turned higher and approached its 52-week high; the early selling reflected the fact that part of the earnings beat came from one-time tariff refunds. The next thing to watch is whether fourth-quarter organic growth comes in above 4%.

Revenue Growth (YoY): + 9%
EPS Surprise: + 4%
Post-Earnings Reaction: + 1.0%

In 30 SecondsRevenue of $12.14 billion beat estimates by 1.6%, and adjusted EPS of $6.68 beat by 4.4%.

Analyzed This Week

19 AnalysesShow All

LMTQ3 2026HOLD · 62

Latest Earnings Analyses

All This Week Media & Telecom Financials Industrials Technology Consumer Staples Semiconductors Consumer Health Care Utilities Energy Materials

By Date By Score By Reaction

Reaction strips share one scale: ±10%

TMO
Thermo Fisher Scientific · Q3 2026
62
VerdictHOLD
First Reaction▲ 1.0%
Revenue YoY
▲ 9%
EPS vs Estimate
+ 4.4%
Oct 21 · Pre-Market
UNH
UnitedHealth Group · Q3 2026
73
VerdictBUY
First Reaction▼ 0.2%
Revenue YoY
▼ 0%
EPS vs Estimate
+ 13.3%
Oct 13 · Pre-Market
JNJ
Johnson & Johnson · Q3 2026
56
VerdictHOLD
First Reaction▼ 5.7%
Revenue YoY
▲ 6%
EPS vs Estimate
+ 2.4%
Oct 13 · Pre-Market
LLY
Eli Lilly and Co · Q2 2026
85
VerdictBUY
First Reaction▲ 4.9%
Revenue YoY
▲ 48%
EPS vs Estimate
+ 27.0%
Aug 5 · Pre-Market
AMGN
Amgen Inc · Q2 2026
78
VerdictBUY
First Reaction▲ 4.6%
Revenue YoY
▲ 10%
EPS vs Estimate
+ 12.0%
Aug 4 · After Close
MRK
Merck & Co · Q2 2026
56
VerdictHOLD
First Reaction▲ 0.2%
Revenue YoY
▲ 5%
EPS vs Estimate
+ 50.0%
Aug 4 · Pre-Market
ABBV
AbbVie Inc · Q2 FY2026
74
VerdictBUY
First Reaction▼ 2.5%
Revenue YoY
▲ 10%
EPS vs Estimate
+ 0.3%
Jul 31 · Pre-Market